hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06291389, orgStudyIdInfo id: RC.2.8.2023, briefTitle: Intraoperative Peak Airway Pressure Changes on Postoperative Pulmonary Function After Muscle Plication, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-10, primaryCompletionDateStruct date: 2024-05-15, completionDateStruct date: 2024-05-15, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: Al-Azhar University, class: OTHER, collaborators name: Benha University, descriptionModule briefSummary: An abdominal panniculus excision procedure is known as an abdominoplasty (panniculectomy). Musculofascial plication is a crucial aspect of abdominoplasty, especially for patients with significant divarication of the recti muscles. This study aimed to evaluate the effect of intraoperative changes in peak airway pressure (PAP) after muscle plication on postoperative pulmonary function., conditionsModule conditions: Abdominal Compartment Syndrome, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 120, type: ESTIMATED, outcomesModule primaryOutcomes measure: Intraoperative peak airway pressure (PAP), secondaryOutcomes measure: Duration of oxygen therapy, secondaryOutcomes measure: Post operative Tidal Volume (Vt) (Measured by spirometer), secondaryOutcomes measure: Post operative Respiratory Rate (RR), secondaryOutcomes measure: Hospital stay., eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: Neveen Kohaf, city: Tanta, zip: 11865, country: Egypt, contacts name: Haney Bauiomy, role: PRINCIPAL_INVESTIGATOR, contacts name: Ahmed Abosakaya, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 30.78847, lon: 31.00192, hasResults: False
protocolSection identificationModule nctId: NCT06291337, orgStudyIdInfo id: Pro2019001483, secondaryIdInfos id: 10-204Mc, type: OTHER, domain: Rutgers IRB, briefTitle: Ibuprofen Inhibits Human Sweet Taste, statusModule overallStatus: COMPLETED, startDateStruct date: 2020-06-01, primaryCompletionDateStruct date: 2023-09-01, completionDateStruct date: 2023-09-30, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: Rutgers, The State University of New Jersey, class: OTHER, collaborators name: Monell Chemical Senses Center, descriptionModule briefSummary: The sweet taste receptor, TAS1R2-TAS1R3, is expressed both orally, where it signals sweet taste, and extraorally in the intestine and pancreas, where it may affect glucose absorption and metabolism. Recently, ibuprofen and naproxen have been identified to inhibit human T1R3 when heterologously expressed in cells. In the present study, the initial objective was to determine if ibuprofen and naproxen inhibit interactions of sugars with human sweet taste receptor under normal, physiological conditions. Ten healthy participants were asked to rate sweetness intensity for a range of sweet stimuli (sucrose, fructose, sucralose) after a prerinse of ibuprofen, naproxen or water. Both ibuprofen and naproxen inhibited sweet taste intensity in a dose-dependent manner. In association studies, ibuprofen use has been linked to preserved metabolic function, as its use is correlated with lower rates of Alzheimer's disease, diabetes and colon cancer. Here the investigators present a potential novel pathway for systemic ibuprofen to impact these metabolic diseases., conditionsModule conditions: Treatment of Sweet Taste Receptors Without or With an Oral Rinse of Ibuprofen Solution in Healthy Participants, conditions: Treatment of Sweet Taste Receptors Without or With an Oral Rinse of Naproxen Solution in Healthy Participants, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: CROSSOVER, interventionModelDescription: We are testing individual sin a within subject control for their sweet taste ratings of sugars without and with oral rinses of ibuprofen and naproxen., primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, enrollmentInfo count: 32, type: ACTUAL, armsInterventionsModule interventions name: Inhibition of Sweet Taste by Ibuprofen Oral Rinses, interventions name: Inhibition of Sweet Taste by Naproxen Oral Rinses, outcomesModule primaryOutcomes measure: Sweet taste ratings, primaryOutcomes measure: Sugar detection thresholds, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Food Science and Nutritional Sciences, city: New Brunswick, state: New Jersey, zip: 08901, country: United States, geoPoint lat: 40.48622, lon: -74.45182, hasResults: False
protocolSection identificationModule nctId: NCT06291324, orgStudyIdInfo id: IRB00103472, secondaryIdInfos id: LCI-SUPP-CRF-WATD-001, type: OTHER, domain: Atrium Health, briefTitle: WATD and Cancer-Related Fatigue: A Study For Patients Undergoing Anti-Cancer Treatment, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2025-12-15, completionDateStruct date: 2025-12-15, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: Wake Forest University Health Sciences, class: OTHER, collaborators name: Atrium Health Levine Cancer Institute, descriptionModule briefSummary: The purpose of this study is to evaluate the feasibility of using a commercial WATD (Wearable Activity Tracker Device) to collect HRV (Heart Rate Variability) data from pancreatic and breast cancer patients., conditionsModule conditions: Pancreatic Cancer, conditions: Breast Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 46, type: ESTIMATED, outcomesModule primaryOutcomes measure: Adherence and acceptability, secondaryOutcomes measure: Theme, secondaryOutcomes measure: Heart rate variability (HRV), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Levine Cancer Institute, city: Charlotte, state: North Carolina, zip: 28204, country: United States, contacts name: Alicia Patrick, role: CONTACT, phone: 980-292-1746, email: alicia.patrick@atriumhealth.org, contacts name: Dori Beeler, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 35.22709, lon: -80.84313, hasResults: False
protocolSection identificationModule nctId: NCT06291311, orgStudyIdInfo id: MT_NIPP-HPV_ERBE, briefTitle: Non-Invasive Plasma Treatment for Cervical Infections: Targeting High- and Low-Risk HPV Variants, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-12-27, primaryCompletionDateStruct date: 2024-06, completionDateStruct date: 2025-12, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: University Hospital Tuebingen, class: OTHER, descriptionModule briefSummary: This is a prospective, single-center, observational proof-of-principle clinical trial at the Department of Women's Health of the University Hospital Tübingen., conditionsModule conditions: HPV Infection, conditions: Cervical Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Cold physical Plasma, interventions name: Control group, outcomesModule primaryOutcomes measure: HPV eradication rate, secondaryOutcomes measure: Correlation of HPV Genotyping, secondaryOutcomes measure: HPV-Quality-of-Life (HPV-QoL), secondaryOutcomes measure: Tissue Tolerance and Compatibility of NIPP Treatment, secondaryOutcomes measure: Detection of Intracellular Molecular Plasma Mechanisms, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University Hospital Tuebingen, Department of Women's Health, status: RECRUITING, city: Tuebingen, zip: 72076, country: Germany, contacts name: Martin Weiss, Dr. med., role: CONTACT, phone: +4970712982211, email: martin.weiss@med.uni-tuebingen.de, geoPoint lat: 48.52266, lon: 9.05222, hasResults: False
protocolSection identificationModule nctId: NCT06291298, orgStudyIdInfo id: STUDY006542, briefTitle: Novel Adaptive Cognitive Training in Autistic Adults With Co-occurring Insomnia, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2025-03-01, completionDateStruct date: 2025-04-01, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: University of South Florida, class: OTHER, descriptionModule briefSummary: The proposed study will test the usability and feasibility of a novel cognitive training (COGMUSE) for autistic adults with co-occurring insomnia (COGMUSE- AUT). Participants (n=15) will complete the cognitive training intervention for 60 minutes per day, 3 times per week for 6 weeks at home totaling to 18 hours. Weekly check-ins will be conducted by study staff over Teams to ensure adherence to the treatment and provide an opportunity for qualitative feedback on the game sessions played. During these 6 weeks, participants will fill out daily (2x/day) electronic sleep diaries and wear an actigraph device (GENEActiv). GENEActiv is a watch-like device that monitors light and movement activity., conditionsModule conditions: Autism Spectrum Disorder, conditions: Insomnia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Pilot test COGMUSE-AUT in a small sample of autistic adults with co-occurring insomnia on primary and secondary outcomes., primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 15, type: ESTIMATED, armsInterventionsModule interventions name: COGMUSE-AUT, outcomesModule primaryOutcomes measure: Objective Cognition-National Institute of Health Toolbox, secondaryOutcomes measure: Objective Slee-Daily Actigraphy, secondaryOutcomes measure: Subjective Sleep- Electronic Daily Sleep Diaries, secondaryOutcomes measure: Insomnia Severity Index, secondaryOutcomes measure: Sleep Habits Questionnaire, secondaryOutcomes measure: Pre-Sleep Arousal, secondaryOutcomes measure: WHO Quality of Life-BREF, secondaryOutcomes measure: Mood, secondaryOutcomes measure: Depression, secondaryOutcomes measure: Adaptive Behavior Assessment System (ABAS-III), secondaryOutcomes measure: Game-related experience (completed during intervention), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06291272, orgStudyIdInfo id: FMHS 328-0723, briefTitle: Effect of Methylcellulose or Psyllium on Fermentation of inUlin Assessed USing MRI, acronym: RUFUS, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-10-15, primaryCompletionDateStruct date: 2024-06-30, completionDateStruct date: 2024-10-30, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: University of Nottingham, class: OTHER, collaborators name: Quadram Institute Bioscience, descriptionModule briefSummary: Our challenge is to understand how fibre interacts with whole-gut function to alter colonic fermentation of FODMAPs. We will exploit the recent availability of a range of food grade modified celluloses which can form gels at body temperature to perform human studies to explore whether the beneficial effect of psyllium is unique or will be found with all gelling substances (4). We are currently performing the COCOA2 study using a modified methylcellulose (results awaited). We now wish to perform a pilot study to image what happens in the colon when methylcellulose is ingested to enable us to plan the next step in our research programme., conditionsModule conditions: Colon, Irritable, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, interventionModelDescription: 3 way cross -over, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: TRIPLE, maskingDescription: Opaque plastic bags containing test meals prepared by some one not involved in analysis pf results, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 18, type: ESTIMATED, armsInterventionsModule interventions name: Psyllium, interventions name: Methylcellulose, interventions name: Inulin, interventions name: Maltodextrin, outcomesModule primaryOutcomes measure: colonic gas volume, secondaryOutcomes measure: colonic gas volume at 6 hours, secondaryOutcomes measure: Breath hydrogen, secondaryOutcomes measure: Oro-cecal transit time, secondaryOutcomes measure: 24 hour breath hydrogen, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Nottingham Digestive Disease Centre, status: RECRUITING, city: Nottingham, state: Nottinghamshire, zip: NG7 2UH, country: United Kingdom, contacts name: Alaa Alhasani, BSc, role: CONTACT, phone: 01159429924, email: alyaa11@exmail.nottingham.ac.uk, contacts name: Robin Spiller, role: CONTACT, phone: +447824328319, email: robin.spiller@nottingham.ac.uk, geoPoint lat: 52.9536, lon: -1.15047, hasResults: False
protocolSection identificationModule nctId: NCT06291246, orgStudyIdInfo id: 23-1823, secondaryIdInfos id: K12TR004416-01, type: NIH, link: https://reporter.nih.gov/quickSearch/K12TR004416-01, briefTitle: Expediting Access to Services for Equity (EASE), acronym: EASE, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2026-06-30, completionDateStruct date: 2026-06-30, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: University of North Carolina, Chapel Hill, class: OTHER, collaborators name: National Center for Advancing Translational Sciences (NCATS), descriptionModule briefSummary: The goal of this clinical trial is to assess whether telehealth-based Family Navigation (FN) expedites enrollment (e.g., reduces time in days) in community-based autism intervention for Black toddlers under the age of 3 after their initial diagnosis of autism.The main questions it aims to answer are:* Does Family Navigation decrease the time to initiation of intervention for Black toddlers with autism?* Does Family Navigation improve developmental outcomes at 18 months post-diagnosis of autism?* Does Family Navigation improve caregiver well-being?Caregivers in the Family Navigation condition will receive 4 research-based individual sessions with a trained navigator to support them in identifying and enrolling in recommended autism early intervention services. All navigation sessions will be delivered virtually via phone/Zoom.Researchers will compare participants who receive family navigation to participants who receive the standard of care (educational materials) to see if family navigation outperforms the standard of care., conditionsModule conditions: Autism Spectrum Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 86, type: ESTIMATED, armsInterventionsModule interventions name: Virtual Family Navigation, interventions name: Educational Materials, outcomesModule primaryOutcomes measure: Time to initiation of autism specific intervention, secondaryOutcomes measure: Caregiver Well-Being Score, secondaryOutcomes measure: Child's Developmental Functioning Score, secondaryOutcomes measure: Child's Adaptive Functioning Score, secondaryOutcomes measure: Appropriateness of Intervention Score, secondaryOutcomes measure: Feasibility of Intervention Score, secondaryOutcomes measure: Acceptability of Intervention Score, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Carolina Institute for Developmental Disabilities, city: Carrboro, state: North Carolina, zip: 27510, country: United States, geoPoint lat: 35.91014, lon: -79.07529, hasResults: False
protocolSection identificationModule nctId: NCT06291207, orgStudyIdInfo id: AD-224P3, briefTitle: A Study to Evaluate the Efficacy and Safety of AD-224, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2024-12, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-06, sponsorCollaboratorsModule leadSponsor name: Addpharma Inc., class: INDUSTRY, descriptionModule briefSummary: The purpose of this study is to evaluate the efficacy and safety of AD-224, conditionsModule conditions: Hypertension,Essential, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 252, type: ESTIMATED, armsInterventionsModule interventions name: AD-224A, interventions name: AD-224B, interventions name: AD-224C, interventions name: Placebo of AD-224A, interventions name: Placebo of AD-224B, interventions name: Placebo of AD-224C, outcomesModule primaryOutcomes measure: Change rate of MSSBP, eligibilityModule sex: ALL, minimumAge: 19 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06291194, orgStudyIdInfo id: 22DE30902, briefTitle: Efficacy and Safety of AJU-S56 5% in Dry Eye Syndrome Patients, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-11-10, primaryCompletionDateStruct date: 2024-05, completionDateStruct date: 2024-05, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: AJU Pharm Co., Ltd., class: INDUSTRY, collaborators name: GL Pharm Tech Corporation, descriptionModule briefSummary: This study is planned to Evaluate the Efficacy and Safety of test drug (AJU-S56 5%) compared to control drug(vehicle) in Patients with Dry Eye Disease., conditionsModule conditions: Dry Eye Syndromes, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 396, type: ESTIMATED, armsInterventionsModule interventions name: AJU-S56 5%, interventions name: Placebo Group(Vehicle), outcomesModule primaryOutcomes measure: Total corneal staining score (TCSS), secondaryOutcomes measure: LGCSS, secondaryOutcomes measure: TFBUT, eligibilityModule sex: ALL, minimumAge: 19 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: AJU Pharm Co., Ltd., status: RECRUITING, city: Seoul, country: Korea, Republic of, contacts name: JUNGMIN LEE, role: CONTACT, phone: +82-02-2630-0700, email: ajuf13001@ajupharm.co.kr, geoPoint lat: 37.566, lon: 126.9784, hasResults: False
protocolSection identificationModule nctId: NCT06291168, orgStudyIdInfo id: CMT002, briefTitle: Comparison of The Effectiveness of Spinal Manipulation and Yoga in Chronic Low Back Pain, acronym: CTESMYCLBP, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2024-03-01, completionDateStruct date: 2024-06-01, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: SEFA HAKTAN HATIK, class: OTHER, descriptionModule briefSummary: The aim of our study was to compare the effectiveness of chiropractic manipulation and yoga-based exercise techniques on pain, functionality, depression and anxiety in patients with long-term low back pain., conditionsModule conditions: Low Back Pain, conditions: Spinal Manipulation, conditions: Yoga, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: The 60 participants will be divided into three groups. These groups will be randomly divided into three groups as chiropractic manipulation group (n=20), yoga-based exercise group (n=20) and conventional exercise group (control group) (n=20). Exercise programs will be performed under the supervision of a physiotherapist. Chiropractic manipulation will be applied to the lumbar region and sacroiliac joint in the side lying position. Data will be analyzed in SPSS 29.0 IBM program. Kruskal-Wallis H test will be used for difference analysis between groups, Kruskal-Wallis H test will be used for comparisons between groups by taking the differences between measurement times and the significance level will be determined as p\<0.05., primaryPurpose: BASIC_SCIENCE, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Chiropractic Manipulation (HVLA - High Velocity Low Amplitude), interventions name: Yoga-Based Exercise Program, interventions name: Conventional Exercises, outcomesModule primaryOutcomes measure: Numeric Rating Scale (NRS), primaryOutcomes measure: Roland-Morris Disability Questionnaire, primaryOutcomes measure: Hospital Anxiety and Depression Scale (HADS), primaryOutcomes measure: Range of Motion (ROM), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False